Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1978 2
1986 2
1987 1
1991 2
1992 1
1995 1
1998 3
2000 1
2008 1
2009 4
2011 1
2012 1
2013 2
2014 1
2015 3
2017 1
2018 2
2019 1
2022 1
2023 2
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.
Brunet L, Alexandre D, Lee J, Blanquer-Rosselló MDM, Bracquemond D, Guernet A, Chhouri H, Goupil M, Kherrouche Z, Arabo A, Mancini M, Cartier D, Yao S, Godefroy D, Dehedin J, Li JR, Duparc C, Jamme P, Vinchent A, Bérard C, Tulasne D, Arena S, Bardelli A, Cheng C, Cho BC, Wurtz O, Coulouarn C, Maraver A, Aaronson SA, Cortot AB, Anouar Y, Grumolato L. Brunet L, et al. Among authors: goupil m. Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w. Nat Commun. 2025. PMID: 40846697 Free PMC article.
Identifying serious underlying diagnoses among patients with brief resolved unexplained events (BRUEs): a Canadian cohort study.
Nama N, Lee Z, Picco K, Jin F, Bone JN, Quet J, Foulds J, Gagnon JA, Novak C, Parisien B, Donlan M, Goldman RD, Sehgal A, Kanani R, Holland J, Kyrychenko P, Kirolos N, Opotchanova I, Harnois É, Schacter A, Frizon-Peresa E, Rajasegaran P, Hosseini P, Wyslobicky M, Akbaroghli S, Nalan P, Mahant S, Tieder J, Gill P; Canadian BRUE Collaboration (C-BRUE-C) and the Canadian Paediatric Inpatient Research Network (PIRN). Nama N, et al. BMJ Paediatr Open. 2024 Sep 24;8(1):e002525. doi: 10.1136/bmjpo-2024-002525. BMJ Paediatr Open. 2024. PMID: 39317653 Free PMC article.
External Validation of Brief Resolved Unexplained Events Prediction Rules for Serious Underlying Diagnosis.
Nama N, Shen Y, Bone JN, Lee Z, Picco K, Jin F, Foulds JL, Gagnon JA, Novak C, Parisien B, Donlan M, Goldman RD, Sehgal A, Holland J, Mahant S, Tieder JS, Gill PJ; Canadian BRUE Collaboration (C-BRUE-C) and the Canadian Paediatric Inpatient Research Network (PIRN). Nama N, et al. JAMA Pediatr. 2025 Feb 1;179(2):188-196. doi: 10.1001/jamapediatrics.2024.4399. JAMA Pediatr. 2025. PMID: 39680379
Sequential therapy in renal cell carcinoma.
Escudier B, Goupil MG, Massard C, Fizazi K. Escudier B, et al. Among authors: goupil mg. Cancer. 2009 May 15;115(10 Suppl):2321-6. doi: 10.1002/cncr.24241. Cancer. 2009. PMID: 19402067 Free article. Review.
A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies.
Ivison S, Malek M, Garcia RV, Broady R, Halpin A, Richaud M, Brant RF, Wang SI, Goupil M, Guan Q, Ashton P, Warren J, Rajab A, Urschel S, Kumar D, Streitz M, Sawitzki B, Schlickeiser S, Bijl JJ, Wall DA, Delisle JS, West LJ, Brinkman RR, Levings MK. Ivison S, et al. Among authors: goupil m. JCI Insight. 2018 Dec 6;3(23):e121867. doi: 10.1172/jci.insight.121867. JCI Insight. 2018. PMID: 30518691 Free PMC article.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Rassy E, et al. Among authors: goupil mg. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. Clin Genitourin Cancer. 2022. PMID: 35977881 Clinical Trial.
38 results